Notice on Resignation of Independent Board Director
Filed with TSE · · 2 pages · English
Earlier from Heartseed
- Non-consolidated Financial Results for the Six Months Ended June 30, 2026 (Under Japanese GAAP)
- Notice Regarding the First Patient Dosed in the Phase I/II company-sponsored Clinical Trial of HS-005 (Catheter Administration) for Cardiac Remuscular
Later from Heartseed
- Notice Regarding the First Patient Dosed in the Ischemic Heart Disease Cohort in the Phase I/II company-sponsored Clinical Trial of HS-005
- Notice Regarding Designation of Allogeneic iPSC-Derived Cardiomyocyte Spheroids "HS-001" as an "Orphan Regenerative Medical Product" by the MHLW
- Notice Regarding Designation of Allogeneic iPS Cell-Derived Cardiomyocyte Spheroids "HS-001" as a "SAKIGAKE Regenerative Medical Product" by the MHLW
- Non-consolidated Financial Results for the Nine Months Ended September 30, 2026 (Under Japanese GAAP)
Follow Heartseed into a list and get an email when it puts out news.
Follow Heartseed